Deals
Mylan, Lupin Said to Weigh Bids for Bayer Dermatology Unit
- Other drugmakers joining fray said to be Leo, Cadila, Torrent
- Non-binding bids are said to be due as soon as this week
This article is for subscribers only.
Drugmakers including Mylan NV and Lupin Ltd. are considering bids for Bayer AG’s dermatology business as the German company sells assets ahead of its $66 billion acquisition of Monsanto Co.
Leo Pharma A/S, Cadila Healthcare Ltd. and Torrent Pharmaceuticals Ltd. are also weighing offers, the people said, asking not to be identified because the deliberations are private. Non-binding bids for Bayer’s dermatology unit, which could fetch more than 1 billion euros ($1.1 billion), may be due as soon as this week, the people said. No final decisions have been made, and the companies may decide against making an offer, they said.